Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Tenax Therapeutics has a “Moderate Buy” consensus rating from nine brokerages: seven rate it a buy, one a strong buy, and one a sell. The average 12-month price target is $37.67, well above the reported share price of $13.44.
• Recent analyst actions have generally been positive, including Piper Sandler raising its price target to $50, while Canaccord Genuity and Evercore initiated coverage with buy or outperform ratings and targets ranging from $35 to $39.
• Tenax reported quarterly EPS of -$0.35, beating the consensus estimate of -$0.38. Institutional ownership remains limited at 1.67%, while the stock trades near $13.44 versus a 52-week range of $5.78 to $19.40.

Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $37.6667.

Several brokerages recently commented on TENX. Piper Sandler lifted their price objective on Tenax Therapeutics from $20.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, June 12th. Canaccord Genuity Group started coverage on Tenax Therapeutics in a research note on Tuesday, July 28th. They set a "buy" rating and a $35.00 price target for the company. Evercore initiated coverage on shares of Tenax Therapeutics in a research note on Wednesday, July 22nd. They issued an "outperform" rating and a $39.00 price objective on the stock. Guggenheim reissued a "buy" rating and issued a $40.00 price objective (up from $34.00) on shares of Tenax Therapeutics in a report on Monday, June 22nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Tenax Therapeutics in a research report on Tuesday, June 30th.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TENX. ADAR1 Capital Management LLC raised its stake in shares of Tenax Therapeutics by 19.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 63,673 shares of the specialty pharmaceutical company's stock worth $776,000 after buying an additional 10,245 shares during the period. Letko Brosseau & Associates Inc. bought a new position in shares of Tenax Therapeutics during the 4th quarter valued at approximately $130,000. Virtu Financial LLC purchased a new stake in Tenax Therapeutics in the 3rd quarter worth approximately $92,000. Corient Private Wealth LLC purchased a new stake in Tenax Therapeutics in the 4th quarter worth approximately $151,000. Finally, Bank of America Corp DE raised its stake in Tenax Therapeutics by 391.2% during the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company's stock worth $297,000 after acquiring an additional 14,789 shares during the period. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $13.44 on Monday. The company has a 50 day simple moving average of $13.79 and a two-hundred day simple moving average of $13.49. Tenax Therapeutics has a fifty-two week low of $5.78 and a fifty-two week high of $19.40. The company has a market capitalization of $502.98 million, a price-to-earnings ratio of -9.08 and a beta of 0.93.

Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03. On average, analysts forecast that Tenax Therapeutics will post -1.44 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company's proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax's lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source